Three active equity "double base" funds have been born in the year, all of them from innovative drugs.

Since the beginning of this year, the innovative pharmaceutical sector has gradually accumulated investment heat, and three doubling funds have emerged from actively managed equity funds, all of which come from the innovative pharmaceutical sector. Among them, the Great Wall Pharmaceutical Industry Selection fund leads this year's active equity funds with a return of 119.66%; the Yongwin Pharmaceutical Innovation Select and the Bank of China Hong Kong Stock Connect Pharmaceutical Fund also soared at the same time, with a year-to-date return of 106.37% and 105.43% respectively.